Halozyme Therapeutics | HALO - Operating Profit

Stock Price
65.40
Daily Change
1.80 2.83%
Monthly
-4.02%
Yearly
7.83%
Q2 Forecast
62.55

Halozyme Therapeutics reported $-88.41M in Operating Profit for its fiscal quarter ending in December of 2025.





Operating Profit Change Date
Acadia Pharmaceuticals USD 17.39M 18.36M Dec/2025
Agios Pharmaceuticals USD -121.58M 4.71M Dec/2025
Alnylam Pharmaceuticals USD 29.4M 59.36M Dec/2025
Amarin USD -2.26M 564K Dec/2025
Amgen USD 3.96B 464M Dec/2025
Baxter International USD -214.2M 415.4M Dec/2025
Cara Therapeutics USD -5.94M 3.55M Sep/2025
Cytokinetics USD -178.37M 11.61M Dec/2025
DBV Technologies USD -34.28M 6.83M Sep/2025
Eli Lilly USD 8.99B 599.9M Dec/2025
Esperion Therapeutics USD 85.23M 95.19M Dec/2025
Halozyme Therapeutics USD -88.41M 306.33M Dec/2025
Intrexon USD -60.84M 26.62M Jun/2024
Ionis Pharmaceuticals USD -215M 54.82M Dec/2025
MannKind USD -69.24M 28.19M Dec/2025
Minerva Neurosciences USD -21.85M 17.48M Dec/2024
Nektar Therapeutics USD -19.09M 15.26M Dec/2025
Pfizer USD 4.65B 3.99B Dec/2025
Rigel Pharmaceuticals USD 14.06M 13.61M Sep/2024
United Therapeutics USD -14.6M 403.9M Dec/2025
Vanda Pharmaceuticals USD -40.66M 29.66M Dec/2024